US: Pharma merger breezes through antitrust clearance

By CPI | September 15, 2013

Pharmaceutical companies Cubist and Optimer announced Friday US antitrust regulators have effective cleared their merger following the expiration of the merger waiting period. As a result, Cubist Pharmaceuticals will acquire all outstanding common Optimer stock, according to reports.

Despite regulatory approval, the transaction remains subject to shareholder clearance as well.